Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB3 | Q16875 | 8/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.64 |
| ▸ | CYP1A1 | P04798 | 9/20 | 0.47 |
| ▸ | CYP1B1 | Q16678 | 9/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | P4HB | P07237 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pfk-158 SCHEMBL15287560 | 1.00 | PFKFB3 (1.00) | PFKFB3HDAC6CYP1A1CYP1B1MAOB | |
| Pfk-158 SCHEMBL15287558 | 1.00 | PFKFB3 (1.00) | PFKFB3HDAC6CYP1A1CYP1B1MAOB | |
| Pfk-158 SCHEMBL29534190 | 1.00 | PFKFB3 (1.00) | PFKFB3HDAC6CYP1A1CYP1B1MAOB | |
| SCHEMBL18807492 | 0.85 | PFKFB3 (0.74) | PFKFB3HDAC6L3MBTL1 | |
| SCHEMBL15309127 | 0.81 | PFKFB3 (1.00) | PFKFB3HDAC6CYP1A1CYP1B1 | |
| SCHEMBL10309045 | 0.81 | PFKFB3 (1.00) | PFKFB3HDAC6CYP1A1CYP1B1 | |
| SCHEMBL5090111 | 0.79 | PFKFB3 (0.65) | PFKFB3HDAC6CYP1A1CYP1B1MAOB | |
| SCHEMBL5090108 | 0.79 | PFKFB3 (0.65) | PFKFB3HDAC6CYP1A1CYP1B1MAOB | |
| SCHEMBL2702934 | 0.79 | PFKFB3 (1.00) | PFKFB3HDAC6CYP1A1CYP1B1L3MBTL1 | |
| SCHEMBL16534534 | 0.79 | PFKFB3 (1.00) | PFKFB3HDAC6CYP1A1CYP1B1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074989-A1 | METHODS AND COMPOSITIONS FOR TREATING PANCREATIC DISEASE | METANOIA BIO INC (US) | 2025-03-06 | — | — | US | claimed |
| US-20240269111-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR NEOVASCULAR DISEASE | METANOIA BIO INC (US) | 2024-08-15 | — | — | US | claimed |
| US-20240269124-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | METANOIA BIO INC (US) | 2024-08-15 | — | — | US | claimed |
| US-20240262916-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE | METANOIA BIO INC (US) | 2024-08-08 | — | — | US | claimed |
| EP-4340897-A1 | METHODS AND COMPOSITIONS FOR TREATING PANCREATIC AND HEPATIC DISEASE | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | claimed |
| EP-4340835-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | claimed |
| EP-4340836-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | claimed |
| EP-4340896-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR NEOVASCULAR DISEASE | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | claimed |
| WO-2023147055-A1 | COMPOSITIONS COMPRISING A NON-BIOABSORBABLE POLYMER AND METABOLIC INHIBITOR | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2023-08-03 | — | — | WO | claimed |
| WO-2023147048-A1 | COMPOSITIONS COMPRISING A BIOABSORBABLE POLYMER AND METABOLIC INHIBITOR | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2023-08-03 | — | — | WO | claimed |
| WO-2022245711-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | METANOIA BIO INC. (US) | 2022-11-24 | — | — | WO | claimed |
| WO-2022245698-A1 | METHODS AND COMPOSITIONS FOR TREATING PANCREATIC AND HEPATIC DISEASE | METANOIA BIO INC. (US) | 2022-11-24 | — | — | WO | claimed |
| WO-2022245697-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR NEOVASCULAR DISEASE | METANOIA BIO INC. (US) | 2022-11-24 | — | — | WO | claimed |
| WO-2022245702-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE | METANOIA BIO INC. (US) | 2022-11-24 | — | — | WO | claimed |
| US-12630633-B2 | Antibody molecules to PD-1 and uses thereof | NOVARTIS AG (CH) | 2026-05-19 | — | — | US | disclosed |
| US-20250135072-A1 | COMPOSITIONS COMPRISING A BIOABSORBABLE POLYMER AND METABOLIC INHIBITOR | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2025-05-01 | — | — | US | disclosed |
| US-20250074989-A1 | METHODS AND COMPOSITIONS FOR TREATING PANCREATIC DISEASE | METANOIA BIO INC (US) | 2025-03-06 | — | — | US | disclosed |
| WO-2022245711-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | METANOIA BIO INC. (US) | 2022-11-24 | — | — | WO | disclosed |
| CN-114920840-A | Antibody molecules against PD-L1 and uses thereof | 诺华股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-114272371-A | Combination therapy comprising anti-PD-1 antibody molecules | 诺华股份有限公司 | 2022-04-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630633-B2 | Antibody molecules to PD-1 and uses thereof | CD40, CD274, ICOS | PFKFB3 4527/4885HDAC6 3079/4885CYP1A1 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.